[1] Hoofnagle JH, Björnsson ES. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273.
[2] Andrade RJ, Aithal GP, Björnsson ES, et al. EASL clinical practice guidelines: drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261.
[3] 卞兆连, 邵建国, 马雄. 药物性肝损伤与自身免疫性肝炎的鉴别诊断与治疗策略[J]. 临床肝胆病杂志, 2018, 34(6): 1156-1159.
[4] Andrade RJ, Chalasani N, Björnsson ES, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5(1): 58.
[5] Sebode M, Schulz L, Lohse AW. “Autoimmune(-like)” drug and herb induced liver injury: new insights into molecular pathogenesis[J]. Int J Mol Sci, 2017, 18(9): 1954.
[6] Koido M, Kawakami E, Fukumura J, et al. Polygenic architecture informs potential vulnerability to drug-induced liver injury[J]. Nat Med, 2020, 26(10): 1541-1548.
[7] Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2021, 116(5): 878-898.
[8] Gerussi A, Natalini A, Antonangeli F, et al. Immune-mediated drug-induced liver injury: immunogenetics and experimental models[J]. Int J Mol Sci, 2021, 22(9): 4557.
[9] Mcgill MR, Jaeschke H. Animal models of drug-induced liver injury[J]. Biochim Biophys Acta Mol Basis Dis, 2019, 1865(5): 1031-1039.
[10] Czaja AJ. Drug-induced autoimmune-like hepatitis[J]. Dig Dis Sci, 2011, 56(4): 958-976.
[11] Thomas D, Wu TY, Cottagiri M, et al. Induction of drug-induced, autoimmune hepatitis in BALB/c mice for the study of its pathogenic mechanisms[J]. J Vis Exp, 2020, (159): e59174.
[12] Dakhoul L, Ghabril M, Chalasani N. Drug-induced chronic liver injury[J]. J Hepatol, 2018, 69(1): 248-250.
[13] Castiella A, Lucena MI, Zapata EM, et al. Drug-induced autoimmune-like hepatitis: a diagnostic challenge[J]. Dig Dis Sci, 2011, 56(8): 2501-2503.
[14] Stine JG, Chalasani N. Chronic liver injury induced by drugs: a systematic review[J]. Liver Int, 2015, 35(11): 2343-2353.
[15] Hydes T, Wright M, Jaynes E, et al. Nitrofurantoin immune-mediated drug-induced liver injury: a serious complication of a commonly prescribed medication[J]. BMJ Case Rep, 2014, 2014: bcr2013203136.
[16] Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins[J]. Semin Liver Dis, 2009, 29(4): 412-422.
[17] Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: clinical phenotypes, autoimmunity and the role of corticosteroid treatment[J]. J Hepatol, 2022, 76(1): 86-92.
[18] Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements[J]. Hepatology, 2017, 65(1): 363-373.
[19] Nagral A, Adhyaru K, Rudra OS, et al. Herbal immune booster-induced liver injury in the COVID-19 pandemic-a case series[J]. J Clin Exp Hepatol, 2021, 11(6): 732-738.
[20] Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241.e2211.
[21] Teschke R, Danan G. Worldwide use of RUCAM for causality assessment in 81,856 idiosyncratic dili and 14,029 hili cases published 1993-mid 2020: a comprehensive analysis[J]. Medicines, 2020, 7(10): 62.
[22] De Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2017, 15(1): 103-112.e102.
[23] Weber S, Benesic A, Buchholtz ML, et al. Antimitochondrial rather than antinuclear antibodies correlate with severe drug-induced liver injury[J]. Dig Dis, 2021, 39(3): 275-282.
[24] 周晓丽, 梁庆升, 孙颖, 等. 自身免疫样药物性肝损伤研究进展[J]. 肝脏, 2017, 22(5): 460-463.
[25] Delemos AS, Foureau DM, Jacobs C, et al. Drug-induced liver injury with autoimmune features[J]. Semin Liver Dis, 2014, 34(2): 194-204.
[26] Weber S, Benesic A, Rotter I, et al. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis[J]. Liver Int, 2019, 39(10): 1906-1917.
[27] Foureau DM, Walling TL, Maddukuri V, et al. Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis[J]. Clin Exp Immunol, 2015, 180(1): 40-51.
[28] Suzuki A, Brunt EM, Kleiner DE, et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J]. Hepatology, 2011, 54(3): 931-939.
[29] 李变利, 徐丽红. 药物性肝损伤、药物诱导性自身免疫性肝炎和自身免疫性肝炎鉴别诊断研究进展[J]. 实用肝脏病杂志, 2021, 24(4): 460-463.
[30] Martínez-Casas OY, Díaz-Ramírez GS, Marín-Zuluaga JI, et al. Differential characteristics in drug-induced autoimmune hepatitis[J]. JGH Open, 2018, 2(3): 97-104.
[31] Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722.
[32] Lammert C, Zhu C, Lian Y, et al. Exploratory study of autoantibody profiling in drug-induced liver injury with an autoimmune phenotype[J]. Hepatol Commun, 2020, 4(11): 1651-1663.
[33] Bonkovsky HL, Barnhart HX, Foureau DM, et al. Correction: cytokine profiles in acute liver injury-results from the US Drug-Induced Liver Injury Network (DILIN) and the Acute Liver Failure Study Group[J]. PLoS One, 2019, 14(2): e0212394.
[34] Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort[J]. Hepatology, 2019, 69(2): 760-773.
[35] Llewellyn HP, Vaidya VS, Wang Z, et al. Evaluating the sensitivity and specificity of promising circulating biomarkers to diagnose liver injury in humans[J]. Toxicol Sci, 2021, 181(1): 23-34.
[36] 胡江峰, 陆伦根. 药物性肝损伤的规范化诊治策略[J]. 中华医学信息导报, 2021, 36(19): 17.
[37] Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: pros and cons[J]. J Dig Dis, 2019, 20(3): 122-126.
[38] Xia Y, Shi H, Qian C, et al. Modulation of gut microbiota by magnesium isoglycyrrhizinate mediates enhancement of intestinal barrier function and amelioration of methotrexate-induced liver injury[J]. Front Immunol, 2022, 13: 874878.
[39] Liu N, Liu J, Zheng B, et al. Gut microbiota affects sensitivity to immune-mediated isoniazid-induced liver injury[J]. Biomed Pharmacother, 2023, 160: 114400.
[40] Liu Y, Fan L, Cheng Z, et al. Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance[J]. Sci Rep, 2021, 11(1): 1611. |
